{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:04:39Z","timestamp":1761948279140,"version":"3.41.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T00:00:00Z","timestamp":1505088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Laure-Anne Van Bellinghen (Chess in Health, Belgium)"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","healthpolicyjrnl.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Health Policy"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.healthpol.2017.08.010","type":"journal-article","created":{"date-parts":[[2017,9,22]],"date-time":"2017-09-22T02:02:23Z","timestamp":1506045743000},"page":"1303-1312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Optimising the introduction of multiple childhood vaccines in Japan: A model proposing the introduction sequence achieving the highest health gains"],"prefix":"10.1016","volume":"121","author":[{"given":"Baudouin","family":"Standaert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Schecroun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Ethgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleksandr","family":"Topachevskyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoriko","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilse","family":"Van Vlaenderen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.healthpol.2017.08.010_bib0005","doi-asserted-by":"crossref","first-page":"B184","DOI":"10.1016\/j.vaccine.2012.12.032","article-title":"Delivering the promise of the Decade of Vaccines: opportunities and challenges in the development of high quality new vaccines","volume":"31","author":"Keith","year":"2013","journal-title":"Vaccine"},{"issue":"54","key":"10.1016\/j.healthpol.2017.08.010_bib0010","first-page":"656","article-title":"Progress toward vaccines for cholera, dengue, malaria, and Ebola","volume":"2014","author":"Cunningham","year":"2003","journal-title":"Journal of the American Pharmacists Association"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0015","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/S2214-109X(13)70170-0","article-title":"Reassessing the value of vaccines","volume":"2","author":"Barnighausen","year":"2014","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0020","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.4161\/hv.23447","article-title":"Economics of vaccines revisited","volume":"9","author":"Postma","year":"2013","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0025","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(14)70035-0","article-title":"Rotavirus vaccination in Europe: drivers and barriers","volume":"14","author":"Parez","year":"2014","journal-title":"Lancet Infectious Diseases"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0030","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/10899580-000000000-00000","article-title":"Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules","volume":"27","author":"Shillcutt","year":"2009","journal-title":"Pharmacoeconomics"},{"year":"2012","series-title":"Ranking Vaccines A Prioritization Framework: Phase I: Demonstration of Concept and a Software Blueprint","author":"Madharan","key":"10.1016\/j.healthpol.2017.08.010_bib0035"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0040","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2165\/00019053-200321120-00001","article-title":"Integer\/linear mathematical programming models: a tool for allocating healthcare resources","volume":"21","author":"Earnshaw","year":"2003","journal-title":"Pharmacoeconomics"},{"year":"2017","series-title":"Results for Development. Immunization Financing: a resource guide for advocates, policymakers, and program managers","key":"10.1016\/j.healthpol.2017.08.010_bib0045"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0050","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2165\/11591560-000000000-00000","article-title":"Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program","volume":"30","author":"Demarteau","year":"2012","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0055","first-page":"376","article-title":"A review of factors affecting vaccine preventable disease in Japan","volume":"73","author":"Kuwabara","year":"2014","journal-title":"Journal of Medicine & Public Health"},{"year":"2015","series-title":"WHO recommendations for routine immunization. In: Immunization, Vaccines and Biologicals","key":"10.1016\/j.healthpol.2017.08.010_bib0060"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0065","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/11593050-000000000-00000","article-title":"Population- versus cohort-based modelling approaches","volume":"30","author":"Ethgen","year":"2012","journal-title":"Pharmacoeconomics"},{"year":"2017","series-title":"Table 2-1 Overview of annual changes in demographics","key":"10.1016\/j.healthpol.2017.08.010_bib0070"},{"year":"2014","series-title":"Vital Statistics \u22122-22 Life Table","key":"10.1016\/j.healthpol.2017.08.010_bib0075"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0080","doi-asserted-by":"crossref","first-page":"e53864","DOI":"10.1371\/journal.pone.0053864","article-title":"Impact of rotavirus vaccination on hospitalisations in Belgium: comparing model predictions with observed data","volume":"8","author":"Standaert","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0085","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2334-13-25","article-title":"An approximation of herd effect due to vaccinating children against seasonal influenza \u2212 a potential solution to the incorporation of indirect effects into static models","volume":"13","author":"Van Vlaenderen","year":"2013","journal-title":"BMC Infectious Diseases"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0090","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1503\/cmaj.101371","article-title":"An assessment of mumps vaccine effectiveness by dose during an outbreak in Canada","volume":"183","author":"Deeks","year":"2011","journal-title":"Canadian Medical Association Journal"},{"issue":"2","key":"10.1016\/j.healthpol.2017.08.010_bib0095","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/21645515.2015.1102811","article-title":"Pneumococcal serotype distribution in adults with invasive disease and in carrier children in Italy: should we expect herd protection of adults through infants' vaccination?","volume":"12","author":"Azzari","year":"2016","journal-title":"Human Vaccines & Immunotherapeutics"},{"year":"2008","series-title":"Optimization Modelling A Practical Approach","author":"Sarker","key":"10.1016\/j.healthpol.2017.08.010_bib0100"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0105","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0110","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/1471-2407-14-365","article-title":"Modeling optimal cervical cancer prevention strategies in Nigeria","volume":"14","author":"Demarteau","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1478-7547-12-3","article-title":"Budget constraint and vaccine dosing: a mathematical modelling exercise","volume":"12","author":"Standaert","year":"2014","journal-title":"Cost Effectiveness and Resource Allocation"},{"issue":"Suppl. 2","key":"10.1016\/j.healthpol.2017.08.010_bib0120","doi-asserted-by":"crossref","first-page":"B34","DOI":"10.1016\/j.vaccine.2015.02.032","article-title":"Bridging the gap: need for a data repository to support vaccine prioritization efforts","volume":"33","author":"Madhavan","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0125","article-title":"Rapid declines in age group-specific rotavirus infection and acute gastroenteritis among vaccinated and unvaccinated individuals within 1 year of rotavirus vaccine introduction in england and wales","author":"Atchison","year":"2015","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0130","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1016\/j.vaccine.2009.06.035","article-title":"WHO Guide for standardisation of economic evaluations of immunization programmes","volume":"28","author":"Walker","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0135","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.vaccine.2012.11.071","article-title":"Estimating and comparing the clinical and economic impact of paediatric rotavirus vaccination in Turkey using a simple versus an advanced model","volume":"31","author":"Bakir","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0140","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.vaccine.2013.11.049","article-title":"Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths","volume":"32","author":"Van Kriekinge","year":"2014","journal-title":"Vaccine"},{"issue":"iii","key":"10.1016\/j.healthpol.2017.08.010_bib0145","first-page":"1","article-title":"Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making","volume":"13","author":"Andronis","year":"2009","journal-title":"Health Technology Assessment"},{"year":"2010","series-title":"Study on evidence and policy for improving usefulness of vaccines","author":"Kamiya","key":"10.1016\/j.healthpol.2017.08.010_bib0150"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0155","article-title":"Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable haemophilus influenzae protein d conjugate vaccine and 13-valent pneumococcal vaccine in japanese children","author":"Shiragami","year":"2014","journal-title":"Infectious Diseases and Therapy"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0160","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1017\/S0950268811001592","article-title":"Incidence of childhood pneumonia and serotype and sequence-type distribution in Streptococcus pneumoniae isolates in Japan","volume":"140","author":"Tanaka","year":"2012","journal-title":"Epidemiology and Infection"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0165","doi-asserted-by":"crossref","first-page":"e68711","DOI":"10.1371\/journal.pone.0068711","article-title":"Incidence survey of acute otitis media in children in Sado Island, Japan-Sado Otitis Media Study (SADOMS)","volume":"8","author":"Otsuka","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0170","doi-asserted-by":"crossref","first-page":"166","DOI":"10.7883\/yoken.JJID.2004.166","article-title":"Estimation of annual incidence, age-specific incidence rate, and cumulative risk of rotavirus gastroenteritis among children in Japan","volume":"57","author":"Yokoo","year":"2004","journal-title":"Japanese Journal Of Infectious Diseases"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0175","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1016\/j.vaccine.2005.11.068","article-title":"A comparative study of the incidence of aseptic meningitis in symptomatic natural mumps patients and monovalent mumps vaccine recipients in Japan","volume":"25","author":"Nagai","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0180","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.vaccine.2010.12.049","article-title":"The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons","volume":"29","author":"Katayose","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0185","doi-asserted-by":"crossref","first-page":"269","DOI":"10.7883\/yoken.66.269","article-title":"The burden of rotavirus gastroenteritis among Japanese children during its peak months: an internet survey","volume":"66","author":"Nakagomi","year":"2013","journal-title":"Japanese Journal Of Infectious Diseases"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0190","doi-asserted-by":"crossref","first-page":"555","DOI":"10.11150\/kansenshogakuzasshi1970.81.555","article-title":"Cost-effectiveness analysis of routine mumps immunization in Japan","volume":"81","author":"Sugawara","year":"2007","journal-title":"Kansenshogaku Zasshi"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0195","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1016\/j.vaccine.2014.05.020","article-title":"Economic evaluation of vaccination programme of mumps vaccine to the birth cohort in Japan","volume":"32","author":"Hoshi","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0200","article-title":"Vital statistics of Japan","volume":"vol. 3","author":"General Mortality","year":"2015"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0205","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1265\/jjh.63.5","article-title":"Estimation of excess mortality associated with influenza epidemics specific for sex, age and cause of death in Japan during 1987\u20132005","volume":"63","author":"Takahashi","year":"2008","journal-title":"Nihon Eiseigaku Zasshi"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0210","first-page":"369","article-title":"Economics of rotavirus infection: no: 1 a study in Maizuru City","volume":"11","author":"Nishimura","year":"1999","journal-title":"The Journal of Pediatric Infectious Disease and Immunology"},{"issue":"Suppl. 1","key":"10.1016\/j.healthpol.2017.08.010_bib0215","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1086\/431503","article-title":"Incidence and burden of rotavirus gastroenteritis in Japan, as estimated from a prospective sentinel hospital study","volume":"192","author":"Nakagomi","year":"2005","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0220","first-page":"43","article-title":"Parents' utilities for outcomes of occult bacteremia","volume":"154","author":"Bennett","year":"2000","journal-title":"Archives of Pediatrics and Adolescent Medicine"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0225","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0149-2918(96)80188-3","article-title":"A cost-utility analysis of second-line antibiotics in the treatment of acute otitis media in children","volume":"18","author":"Oh","year":"1996","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0230","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/INF.0b013e3181b41506","article-title":"Health-related quality of life lost to rotavirus-associated gastroenteritis in children and their parents: a Canadian prospective study","volume":"29","author":"Brisson","year":"2010","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0235","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/archpediatrics.2010.182","article-title":"Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years","volume":"165","author":"Prosser","year":"2011","journal-title":"Archives of Pediatrics and Adolescent Medicine"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0240","doi-asserted-by":"crossref","first-page":"e1001657","DOI":"10.1371\/journal.pmed.1001657","article-title":"Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial","volume":"11","author":"Tregnaghi","year":"2014","journal-title":"PLOS Medicine"},{"key":"10.1016\/j.healthpol.2017.08.010_bib0245","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(07)61744-9","article-title":"Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study","volume":"370","author":"Vesikari","year":"2007","journal-title":"Lancet"},{"year":"2017","series-title":"Overview of annual changes in demographics","author":"Ministry of Health, Labour and Welfare","key":"10.1016\/j.healthpol.2017.08.010_bib0250"}],"container-title":["Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168851017302233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168851017302233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T21:21:21Z","timestamp":1750886481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168851017302233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0168851017302233"],"URL":"https:\/\/doi.org\/10.1016\/j.healthpol.2017.08.010","relation":{},"ISSN":["0168-8510"],"issn-type":[{"type":"print","value":"0168-8510"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimising the introduction of multiple childhood vaccines in Japan: A model proposing the introduction sequence achieving the highest health gains","name":"articletitle","label":"Article Title"},{"value":"Health Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healthpol.2017.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 GlaxoSmithKline Biologicals SA. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}